Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.

Zobel EH, von Scholten BJ, Goldman B, Persson F, Hansen TW, Rossing P

Diabetes, obesity & metabolism22 Feb 2019Cited by 11 (Europe PMC)

PMID30663196PMCIDPMC6593738DOI10.1111/dom.13638PepBankPUB-30663196

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialOther
In liraglutide-treated adults with type 2 diabetes, good HbA1c responders showed changes in other risk factors similar to low responders.
In plain wordsIn adults with type 2 diabetes taking liraglutide, people who responded well on HbA1c had similar changes in other risk factors as poor responders.
Peptide
Liraglutide
Outcome
No significant changeOther risk factor changes in good versus low HbA1c responders
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
In the liraglutide-treated group, good HbA1c responders showed similar changes in other risk factors analysed to low responders (P ≥ 0.17).
2 context sentences(design, population, supporting numbers)
Summary · context
"Good responders" had a change within the best quartile.
Summary · context
We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes.
Report a problemFND-3066319601
02HumanRandomized controlled trialOther
In liraglutide-treated adults with type 2 diabetes, good body weight responders had a larger HbA1c reduction than low body weight responders (-1.6% vs -1.0%).
In plain wordsIn adults with type 2 diabetes taking liraglutide, those who lost the most weight also had a larger drop in HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change in good versus low body weight responders
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.6%
good body weight responders
HbA1c change
−1%
low body weight responders
Source sentences
Summary
Good body weight responders had a larger reduction in HbA1c than low body weight responders (-1.6 ± 0.94 vs. -1.0 ± 0.82%; P = 0.003), but similar changes in the other risk factors (P ≥ 0.11).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes.
Report a problemFND-3066319602
03HumanRandomized controlled trialOther
In liraglutide-treated adults with type 2 diabetes, good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors.
In plain wordsIn adults with type 2 diabetes taking liraglutide, good and poor responders on blood pressure, kidney or cholesterol had similar changes in other risk factors.
Peptide
Liraglutide
Outcome
No significant changeOther risk factor changes by responder status in SBP, UACR, LDL-cholesterol or eGFR
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes.
Report a problemFND-3066319603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01620489

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Novo Nordisk A/Sn = 27914 Jun 2012 to 20 Aug 2013

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 19 Mar 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.